Tradestie Institutional Equity Comparison Engine
QNRX vs REVB โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
REVB Overall Edge
REVB Captures Institutional Edge (3โ0 Pillars ยท 4โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Revelation Biosciences, Inc. Common Stock (REVB) driven by superior Valuation, Growth & Margin, Momentum & Technical. Fundamentally, QNRX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus REVB at 0.9x Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, QNRX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against REVB sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
REVB
QNRX N/M vs REVB 0.9x Fwd P/E
Growth & Margin Winner
REVB
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner
REVB
1Y -82.5% vs +329.1% ยท 52W Pos 0% vs 75%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
QNRX
NASDAQ
Quoin Pharmaceuticals, Ltd. American Depositary Shares
Pharmaceutical Preparations
$3.36
-5.64% 1D
Market Cap
$17.1M
1M Return
-15.81%
1Y Return
-82.54%
Forward P/E
N/M
Unified AI Score
47.1 / 100
HOLD
Tech 33.0
Fund 55.0
Flow 50.0
Mom 64.0
REVB
NASDAQ
Revelation Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$3.69
-4.16% 1D
Market Cap
$2.1M
1M Return
+2.5%
1Y Return
+329.07%
Forward P/E
0.9x
Unified AI Score
43.7 / 100
HOLD
Tech 38.0
Fund 24.0
Flow 50.0
Mom 36.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
QNRX -82.54%
REVB +329.07%
Spread: +411.61 pp (REVB Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
QNRX TTM Op. Margin: 0.0%
REVB TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on QNRX vs REVB. Trailing 12-month operating profitability (QNRX 0.0% vs REVB 0.0%) and valuation multiples (QNRX N/M vs REVB 0.9x Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | QNRX | REVB | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $17.1M | $2.1M | Larger Scale | QNRX |
| Trailing P/E Ratio Valuation | 8.1x | 0.9x | Lower Multiple | REVB |
| Forward P/E Ratio Valuation | N/M | 0.9x | Lower Multiple | REVB |
| Revenue Growth (YoY) Growth | +0.0% | +0.0% | Higher Growth | Tie |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -142.6% | -133.4% | Higher ROE | REVB |
| 52-Week Range Position Momentum | 0% ($3โ$24) | 75% ($0โ$5) | Stronger Trend | REVB |
| Beta / 30D Volatility Risk Regime | 1.35ฮฒ ยท 72% Vol | 2.90ฮฒ ยท 101% Vol | Lower Realized Risk | QNRX |
| Unified Institutional Score Composite Signal | 47.1 / 100 (HOLD) | 43.7 / 100 (HOLD) | Higher Composite | QNRX |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full QNRX vs REVB Buy Guide
QNRX
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
REVB
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither QNRX nor REVB registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.